Troxipide

CAS No. 30751-05-4

Troxipide( BRN0493078 | Troxipide | Troxipida | Troxipidum )

Catalog No. M13981 CAS No. 30751-05-4

Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG 50 In Stock
1G 99 In Stock

Biological Information

  • Product Name
    Troxipide
  • Note
    Research use only, not for human use.
  • Brief Description
    Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.
  • Description
    Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.(In Vitro):Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.(In Vivo):Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU).Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
  • In Vitro
    Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.
  • In Vivo
    Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU). Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively. Animal Model:Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day) Dosage:10, 20, 40, 60 mg/kg Administration:Oral; daily; 2 weeks Result:The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.Animal Model:NCG and GUG rat Dosage:40 mg/kg for iv Administration:IV Result:Had a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
  • Synonyms
    BRN0493078 | Troxipide | Troxipida | Troxipidum
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    30751-05-4
  • Formula Weight
    294.35
  • Molecular Formula
    C15H22N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 3 mg/mL (10.19 mM); DMSO: 18 mg/mL (61.15 mM)
  • SMILES
    O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2
  • Chemical Name
    3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kusugami K, et al. Dig Liver Dis, 2000, 32(4), 305-31
molnova catalog
related products
  • AF 399

    AF 399 is a CCR4 antagonist. It reverses the tumor-promoting environment.

  • Luteolin-3-O-beta-D-...

    Luteolin-3-O-beta-D-glucuronide is active in the inhibition of nitrite production in macrophages.

  • [Gly28,Cys30]-Amyloi...

    [Gly28,Cys30]-Amyloid β-Protein (1-30)